Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.39 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419292 | 0.87 | PRMT5 (0.47) | PRMT5WDR77SLC29A1ADK | |
| SCHEMBL20419326 | 0.87 | PRMT5 (0.47) | PRMT5WDR77SLC29A1ADK | |
| SCHEMBL23982307 | 0.87 | PRMT5 (0.47) | PRMT5WDR77SLC29A1ADK | |
| SCHEMBL13603565 | 0.86 | PRMT5 (0.44) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL14568724 | 0.84 | SLC29A1 (0.49) | SLC29A1METTL3METTL14ADK | |
| SCHEMBL14568617 | 0.84 | SLC29A1 (0.49) | SLC29A1METTL3METTL14ADK | |
| SCHEMBL27786166 | 0.83 | PRMT5 (0.42) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL15948747 | 0.82 | HSP90AA1 (0.38) | METTL3 | |
| SCHEMBL3168059 | 0.80 | EGFR (0.45) | SLC29A1 | |
| SCHEMBL3168049 | 0.80 | EGFR (0.45) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |